...
首页> 外文期刊>Pharmacological research: The official journal of The Italian Pharmacological Society >SRJ09, a promising anticancer drug lead: Elucidation of mechanisms of antiproliferative and apoptogenic effects and assessment of in vivo antitumor efficacy
【24h】

SRJ09, a promising anticancer drug lead: Elucidation of mechanisms of antiproliferative and apoptogenic effects and assessment of in vivo antitumor efficacy

机译:SRJ09,有前途的抗癌药先导:阐明抗增殖和凋亡作用的机制以及体内抗肿瘤功效的评估

获取原文
获取原文并翻译 | 示例
           

摘要

SRJ09 (3,19-(2-bromobenzylidene)andrographolide), a semisynthetic andrographolide (AGP) derivative, was shown to induce G(1) cell cycle arrest and eventually apoptosis in breast and colon cancer cell lines. The present investigation was carried out to elucidate the mechanisms cell cycle arrest and apoptosis and evaluate the in vivo antitumor activity of SRJ09. The in vitro growth inhibitory properties of compounds were assessed in colon (HCT-116) and breast (MCF-7) cancer cell lines. Immunoblotting was utilized to quantitate the protein levels in cells. The gene expressions were determined using reverse transcriptase PCR (RT-PCR). Pharmacokinetic investigation was carried out by determining SRJ09 levels in plasma of Balb/C mice using HPLC. In vivo antitumor activity was evaluated in athymic mice carrying HCT-116 colon tumor xenografts. SRJ09 displayed improved in vitro activity when compared with AGP by producing rapid cell killing effect in vitro. Its activity was not compromised in MES-SA/Dx5 multidrug resistant (MDR) cells expressing p-glycoprotein. Cells treated with SRJ09 (0.1-10 mu M) displayed increased p21 protein level, which corresponded with gene expression. Whereas CDK4 protein level and gene expression was suppressed. The treatment did not affect cyclin Dl. Changes of these proteins paralleled G(1) cell cycle arrest in both cell lines as determined by flow cytometry. Induction of apoptosis by SRJ09 in HCT-116 cells which occurred independent of p53 and bcl-2 was inhibited in the presence of caspase 8 inhibitor, implicating the extrinsic apoptotic pathway. A single dose (100 mg/kg, i.p) of SRJ09 produced a plasma concentration range of 12-30.4 mu M. At 400 mg/kg (q4dX3), it significantly retarded growth of tumor xenografts. The antitumor activity of SRJ09 is suggested mediated via the induction of p21 expression and suppression of CDK-4 expression without affecting cyclin Dl to trigger GI arrest leading to apoptosis. (C) 2016 Elsevier Ltd. All rights reserved.
机译:SRJ09(3,19-(2-溴苄叉基)穿心莲内酯),一种半合成的穿心莲内酯(AGP)衍生物,可诱导G(1)细胞周期停滞并最终导致乳腺癌和结肠癌细胞系凋亡。本研究旨在阐明细胞周期停滞和凋亡的机制,并评估SRJ09的体内抗肿瘤活性。在结肠(HCT-116)和乳腺癌(MCF-7)癌细胞系中评估了化合物的体外生长抑制特性。免疫印迹用于定量细胞中的蛋白质水平。使用逆转录酶PCR(RT-PCR)确定基因表达。通过使用HPLC测定Balb / C小鼠血浆中的SRJ09水平来进行药代动力学研究。在携带HCT-116结肠肿瘤异种移植的无胸腺小鼠中评估了体内抗肿瘤活性。与AGP相比,SRJ09通过在体外产生快速的细胞杀伤作用,显示出更高的体外活性。它的活性在表达p-糖蛋白的MES-SA / Dx5多药耐药(MDR)细胞中没有受到损害。用SRJ09(0.1-10μM)处理的细胞显示出增加的p21蛋白水平,这与基因表达相对应。而CDK4蛋白水平和基因表达被抑制。治疗不影响细胞周期蛋白D1。这些蛋白的变化与流式细胞术确定的两个细胞系中的G(1)细胞周期停滞平行。在caspase 8抑制剂的存在下,SRJ09诱导的HCT-116细胞凋亡独立于p53和bcl-2被抑制,这暗示了外在的凋亡途径。单剂量(100 mg / kg,i.p)的SRJ09产生的血浆浓度范围为12-30.4μM.400mg / kg(q4dX3)时,它显着阻碍了肿瘤异种移植物的生长。建议通过诱导p21表达和抑制CDK-4表达介导SRJ09的抗肿瘤活性,而不影响细胞周期蛋白D1触发GI停滞,从而导致细胞凋亡。 (C)2016 Elsevier Ltd.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号